Experience at Son Espases University Hospital with daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRd) as first line treatment in multiple myeloma

被引：0
|
作者：
Monsonis, Lola Piquer [1 ]
Sampalo, Maria Gali [1 ]
Montana, Albert Perez [1 ]
Raga, Jose Maria Sanchez [1 ]
Mayol, Antonia Sampol [1 ]
机构：
[1] Hosp Univ Son Espases, Palma De Mallorca, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P158
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [21] Lenalidomide, adriamycin and dexamethasone (RAD) versus bortezomib, lenalidomide and dexamethasone (VRD) as induction regimens in newly diagnosed multiple myeloma - first results from the DSMM XIV study
    Knop, S.
    Langer, C.
    Engelhardt, M.
    Stbig, T.
    Schreder, M.
    Dechow, T.
    Muegge, L. -O.
    Bassermann, F.
    Schaefer-Eckart, K.
    Blau, I. -W.
    Wolleschak, D.
    Kropff, M.
    Reichle, A.
    von Metzler, I.
    Metzner, B.
    Roellig, C.
    Hertenstein, B.
    Pfreundschuh, M.
    Duerk, H.
    Biersack, H.
    Ostermann, H.
    Menzel, H.
    Schleicher, J.
    Gramatzki, M.
    Gerecke, C.
    Mueller, M.
    Brueggemann, M.
    Held, S.
    Einsele, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 36 - 36
  • [22] R-CHOP WITH OR WITHOUT LENALIDOMIDE/BORTEZOMIB IN FIRST LINE IN DIFFUSE LARGE CELL LINE B SUBTIPO NON CENTROGERMINAL. EXPERIENCE OF THE HOSPITAL UNIVERSITARI SON ESPASES
    Jimenez-Julia, S. A.
    Bento, L.
    Quintero, A.
    Garcia-Recio, M.
    Martinez-Serra, J.
    Mestre, F.
    Garcia, L.
    Perez, S.
    Aspas, G.
    Lopez Perezagua, P.
    Daumal, J.
    Ramos, R.
    Sampol, A.
    Gutierrez, A.
    HAEMATOLOGICA, 2018, 103 : 285 - 285
  • [23] EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    San-Miguel, J.
    Weisel, K.
    Cook, G.
    Leiba, M.
    Suzuki, K.
    Kumar, S.
    Cavo, M.
    Avet-Loiseau, H.
    Quach, H.
    Hungria, V.
    Lentzsch, S.
    Hajek, R.
    Sonneveld, P.
    Wu, K.
    Qin, X.
    Chiu, C.
    Soong, D.
    Qi, M.
    Schecter, J.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2017, 102 : 1 - 2
  • [24] Carfilzomib, Lenalidomide and Dexamethasone (KRd) Vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) As Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma
    Tan, Carlyn
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Patel, Dhwani
    Maclachlan, Kylee H.
    Lahoud, Oscar B.
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David J.
    Landau, Heather
    Giralt, Sergio A.
    Lesokhin, Alexander M.
    Korde, Neha
    Usmani, Saad
    BLOOD, 2022, 140 : 1817 - 1819
  • [25] Assessing efficacy and tolerability of a modified lenalidomide/bortezomib/dexamethasone (VRd-28) regimen using weekly bortezomib in multiple myeloma
    Rodriguez, Cesar
    Lantz, Jeffrey
    Akbar, Faisal
    Lantz, Lyndsey
    Dressler, Emily
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E217 - E218
  • [26] Bortezomib, Lenalidomide, and Dexamethasone (VRD) Consolidation and Lenalidomide Maintenance in Frontline Multiple Myeloma Patients: Updated Results of the IFM 2008 Phase II VRD Intensive Program
    Roussel, Murielle
    Robillard, Nelly
    Moreau, Philippe
    Benboubker, Lotfi
    Hulin, Cyrille
    Marit, Gerald
    Leleu, Xavier
    Pegourie, Brigitte
    Fruchart, Christophe
    Caillot, Denis
    Stoppa, Anne-Marie
    Facon, Thierry
    Wuilleme, Soraya
    Avet-Loiseau, Herve
    Attal, Michel
    BLOOD, 2011, 118 (21) : 816 - 817
  • [27] First line daratumumab-VTd versus VRd for transplant eligible multiple myeloma
    Byun, Ja Min
    Park, Sung-Soo
    Koh, Youngil
    Min, Chang-Ki
    Yoon, Sung-Soo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S154 - S154
  • [28] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    David S. Siegel
    Gary J. Schiller
    Christy Samaras
    Michael Sebag
    Jesus Berdeja
    Siddhartha Ganguly
    Jeffrey Matous
    Kevin Song
    Christopher S. Seet
    Giampaolo Talamo
    Mirelis Acosta-Rivera
    Michael Bar
    Donald Quick
    Bertrand Anz
    Gustavo Fonseca
    Donna Reece
    William E. Pierceall
    Weiyuan Chung
    Faiza Zafar
    Amit Agarwal
    Nizar J. Bahlis
    Leukemia, 2020, 34 : 3286 - 3297
  • [29] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
    Siegel, David S.
    Schiller, Gary J.
    Samaras, Christy
    Sebag, Michael
    Berdeja, Jesus
    Ganguly, Siddhartha
    Matous, Jeffrey
    Song, Kevin
    Seet, Christopher S.
    Talamo, Giampaolo
    Acosta-Rivera, Mirelis
    Bar, Michael
    Quick, Donald
    Anz, Bertrand
    Fonseca, Gustavo
    Reece, Donna
    Pierceall, William E.
    Chung, Weiyuan
    Zafar, Faiza
    Agarwal, Amit
    Bahlis, Nizar J.
    LEUKEMIA, 2020, 34 (12) : 3286 - 3297
  • [30] Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma
    Nadeem, Omar
    Redd, Robert
    Mo, Clifton
    Laubach, Jacob
    Richardson, Paul G.
    Prescott, Julia
    Marto, Marjorie
    Davie, Christine
    Ricciardi, Caroline
    Murphy, Elizabeth
    Bertoni, Meredith
    Choden, Dechen
    Magidson, Sophie
    Sheehan, Brian
    Shrestha, Hira
    Sperling, Adam S.
    O'Donnell, Elizabeth K.
    Ghobrial, Irene M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S89 - S89
12345